The Phase 1 study of Figitumumab combined with Pegvisomant aimed to evaluate safety and tolerability in patients with advanced solid tumors. The trial was terminated due to recruitment challenges and business considerations, rather than safety concerns. This indicates potential market limitations for this combination therapy, as it may not have demonstrated sufficient efficacy or competitive advantage in a crowded oncology landscape. The combination targets IGF-1R, which is implicated in various cancers, but the competitive landscape includes other therapies targeting similar pathways. Further diligence is warranted to assess the commercial viability of pursuing this combination in future studies or alternative indications.